{{chembox
| ImageFile = Tilomisole.png
| ImageSize = 200px
| IUPACName = [3-(4-Chlorophenyl)[1,3]thiazolo[3,2-a]benzimidazol-2-yl]acetic acid
| OtherNames = 
|Section1={{Chembox Identifiers
| CASNo = 58433-11-7
| PubChem = 42747
| ChEMBL = 2104737
| ChemSpiderID = 38987
| KEGG = D06148
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 651G60U372
| SMILES = Clc4ccc(c1c(sc2nc3ccccc3n12)CC(=O)O)cc4
| InChI = InChI=1S/C17H11ClN2O2S/c18-11-7-5-10(6-8-11)16-14(9-15(21)22)23-17-19-12-3-1-2-4-13(12)20(16)17/h1-8H,9H2,(H,21,22)
  }}
|Section2={{Chembox Properties
| C=17 | H=11 | Cl=1 | N=2 | O=2 | S=1
| MolarMass = 342.80
| Appearance = 
| Density = 
| MeltingPt = 
| BoilingPt = 
| Solubility =
  }}
|Section3={{Chembox Hazards
| MainHazards = 
| FlashPt = 
| AutoignitionPt =
  }}
}}

'''Tilomisole''' ('''WY-18,251''') is an experimental drug which acts as an [[immunomodulator]] and has been studied for the treatment of some forms of cancer.<ref name="pmid6970786">{{cite journal |vauthors=Fenichel RL, Alburn HE, Schreck PA, Bloom R, Gregory FJ |title=Immunomodulating and antimetastatic activity of 3-(p-chlorophenyl) thiazolo[3,2-a]benzimidazole-2-acetic acid (Wy-18,251, NSC 310633) |journal=Journal of Immunopharmacology |volume=2 |issue=4 |pages=491–508 |year=1980 |pmid=6970786 |doi= |url=}}</ref><ref name="pmid1385709">{{cite journal |vauthors=Dillman RO, Ryan KP, Dillman JB, Shawler DL, Maguire R |title=WY 18,251 (Tilomisole), an analog of levamisole: tolerability, and immune modulating effects in cancer patients |journal=Molecular Biotherapy |volume=4 |issue=1 |pages=10–4 |date=March 1992 |pmid=1385709 |doi= |url=}}</ref> 

It can also be seen to contain the arylacetic acid moiety that is endemic to many NSAIDs, e.g. [[ibufenac]].

==References==
{{reflist}}

{{Immunostimulants}}
{{Immunosuppressants}}

[[Category:Immunology]]
[[Category:Experimental cancer drugs]]


{{antineoplastic-drug-stub}}